Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study

키워드

참고문헌 (30)

1. 이희진, "Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients", Journal of Breast Cancer, 16(1), pp.32~39 (2013), 한국유방암학회[DOI]
2. Loi S, "Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer : results from the FinHER trial", Ann Oncol, 25, pp.1544~1550 (2014)
3. Adams S, "Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials : ECOG 2197 and ECOG 1199", J Clin Oncol, 32, pp.2959~2966 (2014)
4. Loi S, "Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy : BIG 02-98", J Clin Oncol, 31, pp.860~867 (2013)
5. Pruneri G, "Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer", Ann Oncol, 27, pp.249~256 (2016)
6. Denkert C, "Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer", J Clin Oncol, 28, pp.105~113 (2010)
7. Denkert C, "Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triplenegative primary breast cancers", J Clin Oncol, 33, pp.983~991 (2015)
8. Salgado R, "Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab : a secondary analysis of the NeoALTTO Trial", JAMA Oncol, 1, pp.448~454 (2015)
9. Ingold Heppner B, "Tumor-infiltrating lymphocytes : a predic-tive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer", Clin Cancer Res, 22, pp.5747~5754 (2016)
10. Salgado R, "The evaluation of tumor-infiltrating lymphocytes(TILs)in breast cancer : recommendations by an International TILs Working Group 2014", Ann Oncol, 26, pp.259~271 (2015)
11. Denkert C, "Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer : results of the ring studies of the international immuno-oncology biomarker working group", Mod Pathol, 29, pp.1155~1164 (2016)
12. Dowsett M, "Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer", J Natl Cancer Inst, 99, pp.167~170 (2007)
13. von Minckwitz G, "Ki67 measured after neoadjuvant chemotherapy for primary breast cancer", Clin Cancer Res, 19, pp.4521~4531 (2013)
14. Dieci MV, "Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer : a retrospective multicenter study", Ann Oncol, 25, pp.611~618 (2014)
15. Hamy AS, "Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer", Ann Oncol, 28, pp.2233~2240 (2017)
16. Garcia-Martinez E, "Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer", Breast Cancer Res, 16, pp.488~ (2014)
17. Watanabe T, "Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive", HER2-negative breast cancers, 2018, pp.168, 135~145
18. Miyashita M, "Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer : a retrospective multicenter study", Breast Cancer Res, 17, pp.124~ (2015)
19. Arnedos M, "Discordance between core needle biopsy(CNB)and excisional biopsy(EB)for estrogen receptor(ER), progesterone receptor(PgR)and HER2 status in early breast cancer(EBC)", Ann Oncol, 20, pp.1948~1952 (2009)
20. Chen X, "Surgery time interval and molecular subtype may influence Ki67change after core needle biopsy in breast cancer patients", BMC Cancer, 15, pp.822~ (2015)
21. Mann GB, "Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer", J Clin Oncol, 23, pp.5148~5154 (2005)
22. Karn T, "Data-driven derivation of cutoffs from a pool of 3, 030Affymetrix arrays to stratify distinct clinical types of breast cancer", Breast Cancer Res Treat, 120, pp.567~579 (2010)
23. Tagliabue E, "Role of HER2 in wound-induced breast carcinoma proliferation", Lancet, 362, pp.527~533 (2003)
24. Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
25. Jeselsohn RM, "Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response", PLoS One, 8, pp.e64225~ (2013)
26. Mathenge EG, "Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model", Neoplasia, 16, pp.950~960 (2014)
27. Vaupel P, "Tumor oxygenation status : facts and fallacies", Adv Exp Med Biol, 977, pp.91~99 (2017)
28. Globerson A, "Ageing of lymphocytes and lymphocytes in the aged", Immunol Today, 21, pp.515~521 (2000)
29. Mao Y, "The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis", PLoS One, 11, pp.e0152500~ (2016)
30. Khan AM, "Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score", Sci Rep, 6, pp.36231~ (2016)

관련 논문AI추천